Acadia Pharmaceuticals (ACAD) Change in Account Payables (2010 - 2026)

Acadia Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 29.43% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was -$5.8 million, a 372.84% decrease from a year earlier, with the FY2025 full-year figure at -$5.3 million, down 291.49% from the prior year.
• Change in Account Payables advanced to $1.3 million in Q1 2026 per ACAD's latest filing, from -$10.8 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $5.2 million in Q4 2023 and bottomed at -$10.8 million in Q4 2025.
• The 5-year median for Change in Account Payables is $1.4 million (2023), against an average of $315882.4.
• Across the five-year window, Change in Account Payables soared 993.26% in 2022 and slumped 275.35% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at $2.7 million in 2022, then jumped by 91.12% to $5.2 million in 2023, then slumped by 155.21% to -$2.9 million in 2024, then slumped by 275.35% to -$10.8 million in 2025, then soared by 112.38% to $1.3 million in 2026.
• Per Business Quant, the three latest ACAD Change in Account Payables figures stand at $1.3 million (Q1 2026), -$10.8 million (Q4 2025), and $1.6 million (Q3 2025).